Relationship Of GSTT1 And GSTM1 Gene Polymorphisms And PAH-DNA Adducts With Pathogenesis Of Multiple Myeloma

Objective To explore the relationship of GSTT1, GSTM1 gene polymorphisms and PAH-DNA adducts with pathogenesis of multiple myeloma.Methods The bone marrow samples from 37 newly-diagnosed MM patients and52 control health peoples were collected; the PCR-based restriction fragment length polymorphisms(PCR-RFLP) method was used to detect the polymorphisms of GSTT1 and GSTM1, and to analysis their relationship with clinical characters of MM patients; the enzyme-linked immune-sorbent assay(ELISA) was performed to detect the concentration of PAH-DNA adducts.Results GSTT1 null and GSTM1 null genotypes had increased the risk of multiple myeloma with OR 2.57(p=0.035) and 1.37(p>0.05) respectively. In MM patients group, GSTT1 null genotype in stage III was significantly higher than that in stages I,II(p=0.038). However,no statistically significant association was found between GSTT1 gene polymorphisms and clinical characters, such as age, type, hemoglobin,β2-MG, albumin. Compared with Hb≥85g/L of the newly-diagnosed MM patients,MM patients with Hb<85g/L had significantly higher incidences of GSTM1 null(p=0.017). The level of PAH-DNA adducts in MM patients was higher than that in controls(2358±1182pg/m L vs 1853±996pg/m L)(p=0.032). GSTT1 null genotype with PAH-DNA level higher(or equal) than 2100pg/m L showed a risk index of MM(OR=4.500,p=0.01).Conclusion GSTT1 gene may have a critical function in the development of MM,and correlates with staging of MM. GSTM1 gene polymorphisms correlates with hemoglobin levels of patients with MM. The content of PAH-DNA adducts may play an important role in the pathogenesis of multiple myeloma.